{"organizations": [], "uuid": "06ce4eafa9808a2804a50016da10978245a2e2f1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-avexis-gene-therapy-awarded-sakiga/brief-avexis-gene-therapy-awarded-sakigake-designation-for-spinal-muscular-atrophy-type-1-idUSFWN1R90JP", "country": "US", "domain_rank": 408, "title": "BRIEF-Avexis Gene Therapy Awarded Sakigake Designation For Spinal Muscular Atrophy Type 1", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-27T15:09:00.000+03:00", "replies_count": 0, "uuid": "06ce4eafa9808a2804a50016da10978245a2e2f1"}, "author": "", "url": "https://www.reuters.com/article/brief-avexis-gene-therapy-awarded-sakiga/brief-avexis-gene-therapy-awarded-sakigake-designation-for-spinal-muscular-atrophy-type-1-idUSFWN1R90JP", "ord_in_thread": 0, "title": "BRIEF-Avexis Gene Therapy Awarded Sakigake Designation For Spinal Muscular Atrophy Type 1", "locations": [], "entities": {"persons": [], "locations": [{"name": "japan", "sentiment": "none"}], "organizations": [{"name": "avexis inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 13 PM / Updated 18 minutes ago BRIEF-Avexis Gene Therapy Awarded Sakigake Designation For Spinal Muscular Atrophy Type 1 Reuters Staff March 27 (Reuters) - Avexis Inc: * AVEXIS GENE THERAPY AWARDED SAKIGAKE DESIGNATION FOR SPINAL MUSCULAR ATROPHY TYPE 1 * AVEXIS INC - DESIGNATION WAS BASED ON DATA FROM PHASE 1 CLINICAL TRIAL OF CO’S PROPRIETARY GENE THERAPY​ * AVEXIS INC - ‍JAPAN’S MINISTRY OF HEALTH, LABOUR AND WELFARE AWARDED INITIAL PRODUCT CANDIDATE, AVXS-101, SAKIGAKE FOR TREATMENT OF SMA TYPE 1​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)", "external_links": [], "published": "2018-03-27T15:09:00.000+03:00", "crawled": "2018-03-27T15:35:41.005+03:00", "highlightTitle": ""}